Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting

Schedule of activity of Company's segments


		For the Three Months Ended March 31,
		2026												2025
		Ophthalmic			Digital			Corporate/						Ophthalmic			Digital			Corporate/
		Technology			Assets			Other			Total			Technology			Assets			Other			Total

Revenue:
Revenue		$	—		$	244,271		$	—		$	244,271		$	14,720		$	—		$	—		$	14,720
Less:
Cost of revenue			—			—			—			—			(48)			—			—			(48)
Gross Income (Loss)			—			244,271			—			244,271			14,672			—			—			14,672
Less:
Research and Development:
Salaries and benefits			123,106			—			—			123,106			420,000			—			—			420,000
Direct clinical and non-clinical expenses			60,841			—			—			60,841			72,657			—			—			72,657
Facilities expenses			11,788			—			—			11,788			70,837			—			—			70,837
Non-cash stock based compensation expenses			38,934			—			—			38,934			64,677			—			—			64,677
Supplies and materials			—			—			—			—			25,130			—			—			25,130
Other Expenses⁽¹⁾			3,880			—			—			3,880			19,742			—			—			19,742
Depreciation expense			48,215			—			—			48,215			—			—			—			—
Realized gain - digital assets and digital assets receivable			—			(3,623,764)			—			(3,623,764)			—			—			—			—
Unrealized gain - digital assets			—			(10,973,979)			—			(10,973,979)			—			—			—			—
Unrealized gain – digital intangible assets receivable			—			(367,251)			—			(367,251)			—			—			—			—
Impairment loss - digital intangible assets			—			1,231,668			—			1,231,668			—			—			—			—
Net gain (loss) on derivative instruments			—			(39,401)			—			(39,401)			—			—			—			—
Provision for credit losses			—			504,511			—			504,511			—			—			—			—
Reacquisition of license rights			—			—			—			—			—			—			—			—
Segment (income) loss			286,764			(13,512,487)			—			(13,225,723)			673,043			—			—			673,043
Reconciling Items
Selling, general and administrative expense⁽²⁾			—			—			4,493,604			4,493,604			2,372,322			—			—			2,372,322
Other (income) expense, net ⁽³⁾			—			—			(108,431)			(108,431)			452,840			—			—			452,840
Net Income (Loss)		$	(286,764)		$	13,512,487		$	(4,385,173)		$	8,840,550		$	(3,483,533)		$	—		$	—		$	(3,483,533)

(1)	Other research and development expenses include outsourced engineering and IT systems used for research and development.

(2)	Selling, general and administrative expenses primarily include professional fees, general and administrative compensation expenses, general strategic consulting, Nasdaq/SEC fees, insurance and facilities expenses.

(3)	Other (income) expense, net includes interest income, interest expense and gain on extinguishment of liabilities.

Schedule of segment assets


		March 31, 2026												December 31, 2025
		Ophthalmic			Digital			Corporate/						Ophthalmic			Digital			Corporate/
		Technology			Assets			Other			Total			Technology			Assets			Other			Total
Segment Assets
Cash		$	—		$	—		$	7,380,922		$	7,380,922		$	—		$	—		$	6,443,467		$	6,443,467
Digital assets			—			60,739,409			—			60,739,409			—			43,872,033			—			43,872,033
All other assets			71,105			—			1,874,527			1,945,632			132,652			—			1,316,104			1,448,756
Total Assets		$	71,105		$	60,739,409		$	9,255,449		$	70,065,963		$	132,652		$	43,872,033		$	7,759,571		$	51,764,256